From: Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping
 | Genotype distributions | AD Case-Control regression | |||
---|---|---|---|---|---|
Group/model | CN, carrier No. / Total No. (%) | AD, carrier No. / Total No. (%) | CN - AD, MAF (%) | OR (95% CI) | P-value |
rs439401 - T allele tested | |||||
 APOE*4/4 - additive model | |||||
  Discovery | 14 / 237 (5.91 %) | 19 / 1652 (1.15 %) | 3.59 % - 0.64 % | 0.10 (0.04, 0.24) | 1.64E-07 |
  Rotterdam | 5 / 150 (3.33 %) | 2 / 86 (2.33 %) | 2.33 % - 1.16 % | 0.43 (0.10, 1.80) | 0.25 |
  EADI | 1 / 62 (1.61 %) | 2 / 205 (0.98 %) | 0.80 % - 0.49 % | 0.37 (0.01, 12.7) | 0.58 |
  EADB | 2 / 195 (1.03 %) | 21 / 956 (2.20 %) | 0.52 % - 1.20 % | 1.61 (0.39, 6.77) | 0.51 |
 APOE*3/4 - WT vs HOM | |||||
  Discovery | 19 / 1401 (1.36 %) | 14 / 2974 (0.47 %) | - | 0.55 (0.38, 0.80) | 1.58E-03 |
  Rotterdam | 8 / 993 (0.81 %) | 3 / 220 (1.36 %) | - | 1.21 (0.31, 4.72) | 0.78 |
  EADI | 4 / 593 (0.67 %) | 5 / 420 (1.19 %) | - | 1.22 (0.60, 2.49) | 0.58 |
  EADB | 12 / 1343 (0.89 %) | 21 / 2070 (1.01 %) | - | 0.80 (0.55, 1.17) | 0.25 |